Investment Thesis — Pfizer Inc.
Pfizer's valuation reflects a post-COVID hangover and assumes its pipeline cannot offset lost vaccine revenue, but the market underestimates the durability of its base pharma business and the impact of cost-cutting. The high dividend yield signals investor skepticism about growth, yet Pfizer's cash flow and pipeline are more resilient than consensus models.
Catalysts
- Pipeline readouts in immunology and oncology
- Execution of cost-cutting and margin improvement
- Strategic buybacks or accretive M&A
Risk Factors
- Pipeline failures or regulatory setbacks
- Dividend cut or cash flow deterioration
- Patent expiries impacting core revenue
Key Debates
New products reverse -2.2% revenue decline by H1 FY25
Seagen acquisition drives 15% oncology growth by Q4
PFE's 9.06 Fwd P/E expands to 12x by Q3 FY25